2nd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$260,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Settlements, Patent Reform, S. 1720 Patent Transparency and Improvments Act of 2013, Patent Abuse Reduction Act

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1720 (113th)

Trade (domestic/foreign) TRD

General Trade Issues, TPP

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax Reform, Tax Extenders, Corporate Tax

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Federal policy regarding Public Law 113-54, the Drug Quality and Security Act; FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including BiologicalProducts," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics; Implementations of Biosimilars in the Affordable Care Act (ACA), Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act; The Generic Drug Pricing Transparency Act, H.R. 4437; Risk Evaluation Mitigation Strategies, Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing

LobbyistCovered position, as disclosed
NIMISH SHAH —
KIMBERLEE TRZECIAK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4437 (113th)

Budget/Appropriations BUD

Global Health Appropriations, President's Emergency Plan for AIDS Relief funding, Global Fund funding; FY 2015 Budget, FY 2015 House and Senate Appropriations, Funding for FDA, Funding for the Office of Generic Drug, Generice Drug User Fees

LobbyistCovered position, as disclosed
NIMISH SHAH —
KIMBERLEE TRZECIAK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.